ASCO Annual Meeting 2015

AstraZeneca and MedImmune presented encouraging results from their novel combination-focused immuno-oncology portfolio at ASCO Annual Meeting 2015

LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results…

9 years ago